StemCell Therapy

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. We can see that China Regenerative Medicine International Limited (HKG:8158) does use debt in its business. But the more important question is: how much risk is that debt creating?

Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. The first step when considering a company's debt levels is to consider its cash and debt together.

View our latest analysis for China Regenerative Medicine International

You can click the graphic below for the historical numbers, but it shows that China Regenerative Medicine International had HK$220.2m of debt in June 2020, down from HK$282.4m, one year before. However, it also had HK$32.4m in cash, and so its net debt is HK$187.8m.

Zooming in on the latest balance sheet data, we can see that China Regenerative Medicine International had liabilities of HK$311.5m due within 12 months and liabilities of HK$163.5m due beyond that. On the other hand, it had cash of HK$32.4m and HK$253.0m worth of receivables due within a year. So it has liabilities totalling HK$189.5m more than its cash and near-term receivables, combined.

Given China Regenerative Medicine International has a market capitalization of HK$1.17b, it's hard to believe these liabilities pose much threat. However, we do think it is worth keeping an eye on its balance sheet strength, as it may change over time. There's no doubt that we learn most about debt from the balance sheet. But it is China Regenerative Medicine International's earnings that will influence how the balance sheet holds up in the future. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend.

In the last year China Regenerative Medicine International wasn't profitable at an EBIT level, but managed to grow its revenue by 358%, to HK$154m. When it comes to revenue growth, that's like nailing the game winning 3-pointer!

Despite the top line growth, China Regenerative Medicine International still had an earnings before interest and tax (EBIT) loss over the last year. Its EBIT loss was a whopping HK$239m. Considering that alongside the liabilities mentioned above does not give us much confidence that company should be using so much debt. Quite frankly we think the balance sheet is far from match-fit, although it could be improved with time. Another cause for caution is that is bled HK$324m in negative free cash flow over the last twelve months. So suffice it to say we consider the stock very risky. The balance sheet is clearly the area to focus on when you are analysing debt. However, not all investment risk resides within the balance sheet - far from it. Be aware that China Regenerative Medicine International is showing 4 warning signs in our investment analysis , and 3 of those shouldn't be ignored...

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

PromotedIf youre looking to trade China Regenerative Medicine International, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Original post:
Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet? - Simply Wall St

New York, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Artificial Joints Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type ; Material ; Application ; End User and Country" - https://www.reportlinker.com/p05989565/?utm_source=GNW North America Artificial Joints market is expected to grow due to factors such as to increasing prevalence of bone and joint conditions, increasing prevalence of obesity, and rising government support by introducing guidelines for regenerative medicines. However, high cost and complications associated with the artificial joint surgery is expected to hinder market growth.

An artificial joint is a device used in orthopedic surgery procedures in which an arthritic or dysfunctional joint surface is surgically replaced.Extensively increasing geriatric population coupled with sedentary lifestyle are the most prevalent conditions for the growth of bone and joint diseases worldwide.

According to a data published by CDC (Centers for Disease Control and Prevention) in 2020, an estimated 32.5 million Americans are suffering from osteoarthritis. Such massive prevalence of bone and joint defects are estimated to have positive impact on the demand of bone replacement procedures, which will eventually drive the market growth during the forecast period. Also, a rising number of sports injuries among athletes is also anticipated to have an impact on the growth of the market by certain extent.

However, due to the negative impact of COVID-19, health care systems are overburdened, and the medical care delivery to all patients has become a challenge in North America. The complete shutdown of businesses offering artificial joints in the United States and several other areas will cause the regions supply chain disruptions.

Based on Product, the North America Artificial Joints market is segmented into cemented joints and non-cemented joints. The cemented joints segment held the largest share of the market in 2019 and is expected to register the highest CAGR in the market during the forecast period.

The North America Artificial Joints market, by material, is segmented into ceramics, alloys, oxinium, others. The ceramic segment held the largest share of the market in 2019, however, alloys segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on Application, the North America Artificial Joints market is segmented into artificial joints of knee, artificial joints of hip, artificial joints of shoulder, others. The artificial joints of knee segment held the largest share of the market in 2019 and is expected to register the highest CAGR in the market during the forecast period.

The North America Artificial Joints market, based on end user, is segmented into artificial joints of hospitals, ambulatory care centers, and other end users. The hospital segment held the largest share of the market in 2019 and is anticipated to register the highest CAGR in the market during the forecast period.

A few of the major primary and secondary sources associated with this report on the North America Artificial Joints market are the US Food and Drug Administration (FDA), International Society of Arthroplasty, Knee Surgery and Orthopedic Sports Medicine (ISAKOS), World Health Organization (WHO) and National Health Service (NHS).Read the full report: https://www.reportlinker.com/p05989565/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Original post:
North America Artificial Joints Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type ; Material ; Application ; End User and...

London, Nov. 25, 2020 (GLOBE NEWSWIRE) -- According to a new market research report Collagen Market by Product (Gelatin, Collagen Peptide, Native Collagen, Synthetic Collagen), Source (Porcine, Bovine, Chicken, Sheep, Other Sources), and Application (Food and Beverages, Pharmaceuticals, Nutraceuticals, Cosmetics, Healthcare) - Global Forecasts to 2027, published by Meticulous Research, in terms of value, the collagen market is expected to grow at a CAGR of 6.9% to reach $7.53 billion by 2027; while in terms of volume, the market is expected to grow at a CAGR of 5.1% to reach 683.8 KT by 2027.

DownloadFree Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5121

The overall collagen market is primarily driven by its growing use in the food industry, growing demand for protein consumption and nutricosmetics, increasing application in healthcare, and growing use of collagen-based biomaterials. In addition, rise in per capita income and booming food processing industry is providing significant opportunities to collagen manufacturers all across the globes. But, safety concerns and improvement in the processing technology are still a challenge for this market. Therefore, safety concerns, religious constraints, and growing use of alternatives are expected to restrain the growth of this market to some extent.

The global collagen market is mainly segmented by type (gelatin, collagen peptide, native collagen, synthetic collagen), source (bovine, porcine, marine, chicken, sheep, and other sources), application (food and beverages, pharmaceuticals, nutraceuticals, healthcare, cosmetics, and technical applications), and geography.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business:https://www.meticulousresearch.com/speak-to-analyst/cp_id=5121

Based on type, the overall collagen market is mainly segmented into gelatin, collagen peptide, native collagen, and synthetic collagen. Gelatin segment is estimated to account for the largest share of the overall collagen market in 2020. The large share of this segment is mainly attributed to the increased demand from the food and pharmaceutical industries, owing to its outstanding stabilizing features and binding characteristics. The nutritional gummies, chewable soft capsules, and enteric capsules are the recent trends in the pharma drug deliveries where mass volume of gelatin is being used. In addition, growing usage of gelatin in photography, nutraceuticals, and cosmeceuticals are also contributing to its large adoption.

Based on source, the overall collagen market is segmented into bovine, porcine, fish, chicken, sheep, and other sources. The bovine collagen segment is estimated to command the largest share of the overall collagen market in 2020. The large share of this segment is mainly attributed to the growing beef consumption and its several health benefits such as skin health, tendon reinforcement, bone loss prevention, and relief from arthritis. However, fish collagen segment is expected to grow at the fastest CAGR during the forecast period. The rapid growth of this segment is mainly attributed to the rising fish production and growing cosmetic industry across the globe.

Based on application, the overall collagen market is mainly segmented into food and beverages, pharmaceuticals, nutraceuticals, healthcare, cosmetics, and technical applications. The food and beverages segment is estimated to command the largest share of the overall collagen market in 2020, mainly attributed to vast applications of collagen across the food and beverages industry due to its unique gelling and surface behavior properties. However, nutraceuticals segment is expected to grow at the highest CAGR during the forecast period. The rapid growth of this segment is mainly attributed to the growing use of nutraceuticals for weight management across the globe.

Quick Buy Collagen Market Research Report: https://www.meticulousresearch.com/buy_now.php?pformat=425&vformat=1261

The global collagen market is divided into six major regions, namely North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East. The North America region accounted for the largest share of the global collagen market in 2020. The largest share of this region is mainly attributed to the huge consumption of cosmeceuticals and nutraceuticals, rise in research and development activities, well established food and healthcare industry, and easy availability of raw materials. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. The fast growth of the region is mainly due to the increasing number of food manufacturers and the prevailing food processing industry particularly in China and India; growing population; rising awareness of nutrition and personal well-being; steady pace of industrialization; high spending on personal care products; and abundant availability of raw material for collagen and gelatin manufacturing.

The key players operating in the global collagen market are Rousselot (The Netherlands), GELITA AG (Germany), Weishardt (France), Tessenderlo Group NV (Belgium), Nitta Gelatin Inc. (Japan), LAPI GELATINE S.p.a. (Italy), ITALGELATINE S.p.A. (Italy), Ewald-Gelatine GmbH (Germany), REINERT GRUPPE Ingredients GmbH (Germany), Trobas Gelatine B.V. (The Netherlands), GELNEX (Brazil), Junc Gelatines SL (Spain), HolistaCollTech Ltd. (Australia), Collagen Solutions Plc. (U.K.), and Advanced BioMatrix, Inc. (U.S.).

To gain more insights into the market with a detailed table of content and figures, click here:https://www.meticulousresearch.com/product/collagen-market-5121/

Scope of the report

Collagen Market, by Type

Collagen Market, by Source

Collagen Market, by Application

Collagen Market, by Geography

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5121

Amidst this crisis, Meticulous Researchis continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here-https://www.meticulousresearch.com/custom-research.php

Related Reports:

Artificial Casings Market by Type (Collagen Casing, Cellulose Casing, Plastic Casing, Fibrous Casing, Value Added Casing, Textile Casing, and Net Casing) and GeographyGlobal Forecast to 2025

https://www.meticulousresearch.com/product/artificial-casings-market-5035/

South East Asian Collagen Market by Product (Collagen Peptide and Gelatin), Source (Porcine, Bovine, Marine, Chicken, Sheep, and Other Animals), Application (Food and Beverages, Cosmetics, Nutraceuticals, Pharmaceuticals, Healthcare, and Technical) Industry Forecast to 2023

https://www.meticulousresearch.com/product/south-east-asia-collagen-market-2023/

Collagen and Gelatin Market for Regenerative Medicine by Type, (Collagen and Gelatin), by Source, (Bovine, Porcine, Marine, and others), by Application, (Orthopedic, Wound Care, Cardiovascular, and others) - Global Forecast to 2022

https://www.meticulousresearch.com/product/collagen-gelatin-market-regenerative-medicine-2022/

About Meticulous Research

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to detail. With meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact:Mr. Khushal BombeMeticulous ResearchDirect Lines: +1-646-781-8004 (North America)+44-203-868-8738 (Europe)+91 744-7780008 (Asia-Pacific)Email- sales@meticulousresearch.comVisit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/press-release/collagen-market-2027/479/

Visit link:
Collagen Market Worth $7.53 billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis by Meticulous Research - GlobeNewswire

NEW YORK & CARLSBAD, Calif.--(BUSINESS WIRE)--Biotech Showcase Digital is the investor conference that drives the future of biotech innovation, digital medicine, and international collaboration. In its 13th year, the conference will be a virtual experience for attendees in an engaging, live and on-demand format delivered through partneringONE between January 1115, 2021. For the first time ever, content and presentations will be released beginning November 30, 2020. Register today to begin scheduling meetings with potential investors and partners.

In just the past five years, 250 companies that presented at Biotech Showcase have generated deals worth more than $61 Billion. The organizers anticipate more than 300 public and private presenting companies this year. A full list of currently registered presenting companies can be found here. More generally, noteworthy conference participants and sponsors include Ajinomoto, Alliance for Regenerative Medicine, Bayer, Global Genes, Novo Nordisk, Silicon Valley Bank and Startup Health.

"One of the industry's largest annual healthcare investor and partnering conferences, Biotech Showcase brings together biopharma and life sciences thought leaders who set the tone and pace for the coming year in biotech," said Tomas Landh, Innovation Sourcing Vice President, Senior Principal Scientist Search and Evaluation at Novo Nordisk. "Every year, our team looks forward to participating in meetings with our existing and potential partners during Biotech Showcase. 2021 will be no different other than the fact that the experience will be delivered in an innovative digital platform."

To make the experience as valuable and seamless as possible, Biotech Showcase offers:

According to Sara Jane Demy, Founder and CEO, Demy-Colton, As we continue navigating these unprecedented times and prepare for the promise of a new year, staying connected within the life sciences industry is more important than ever. In its virtual form, Biotech Showcase will continue to be a place to create a link between investors and the industrys most promising biotech and pharmaceutical companies.

Tina Gunnink, Managing Director, EBD Group US, added Biotech Showcase remains one of the largest investor conferences for the life sciences most innovative companies and is a particularly pivotal touchpoint for those looking for partnerships and investment. We are looking forward to seeing the continued collaboration for Biotech Showcase 2021.

Organizers anticipate more than 2,500 virtual attendees this year and have designed a program to provide them with industry updates and insights from leading executives and advisors as well as key sessions. Conference registration also gives attendees access to the Biotech Showcase program as well as its sister events Digital Medicine & Medtech Showcase and Seed Showcase.

For more information or to register for the event, visit http://www.biotechshowcase.com.

About Demy-Colton

Since 2008, Demy-Colton has been at the forefront of building networks between leaders from innovative biotech companies and industry stakeholders to examine and address biotech opportunities and challenges and deliver on the promise of transformational science.

Demy-Colton achieves this with unique meeting platforms that facilitate networking and biotech community development on an international scale. Aside from Biotech Showcase, its investor and specialized events include BioFuture, CEO Summit Europe, and CEO Summit Napa, Demy-Colton Virtual Salons, and CEO Virtual Dialogues. Its events build networking communities that transcend geographical boundaries and establish ongoing, high-value relationships among the industrys top decision makers, investors, and thought leaders.

Demy-Colton sets a unique stage where investment, learning, and growth thrive. Its events spur introductions and thoughtful conversations. In turn, inspiration, ideas, and opportunities for investment flow.

About EBD Group

EBD Groups overriding mission is to help collaborations get started across the life sciences value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life sciences markets around the world is powered by our state-of-the-art partnering software, partneringONE, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.

Today our events (BIO-Europe, BIO-Europe Spring, BioPharm America, Biotech Showcase, China Showcase, Digital Medicine & Medtech Showcase, ChinaBio Partnering Forum, Rare Disease Innovation and Partnering Summit, and BioEquity Europe) annually attract more than 15,000 senior life sciences executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.

Read more:
13th Annual Biotech Showcase to Bring Together Attendees Digitally in 2021 for Investing, Partnering and Collaboration - Business Wire

Global Regenerative Medicine Products Market Research Report 2020

The Lexis Business Insights added a new report Global Regenerative Medicine Products Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016 2024 in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting.

In 2020, the global Regenerative Medicine Products Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2020-2025.

The global Regenerative Medicine Products Market report offers a complete overview of the Regenerative Medicine Products Market globally. It presents real data and statistics on the inclinations and improvements in global Regenerative Medicine Products Markets. It also highlights manufacturing, abilities & technologies, and unstable structure of the market. The global Regenerative Medicine Products Market report elaborates the crucial data along with all important insights related to the current market status.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the Regenerative Medicine Products market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Get sample copy of thisreport @ https://www.lexisbusinessinsights.com/request-sample-142529

Top key players @ Acelity, DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, Osiris Therapeutics, Vcanbio, Gamida Cell, Golden Meditech, Cytori Therapeutics, Celgene, Vericel Corporation, Guanhao Biotech, Mesoblast, Stemcell Technologes, and Bellicum Pharmaceuticals

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Regenerative Medicine Products market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Regenerative Medicine Products Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Regenerative Medicine Products Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Regenerative Medicine Products Market?

What are the key market trends impacting the growth of the Global Regenerative Medicine Products Market?

What are the challenges to market growth?

Who are the key vendors in the Global Regenerative Medicine Products Market?

What are the market opportunities and threats faced by the vendors in the Global Regenerative Medicine Products Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Regenerative Medicine Products Market;

3.) The North American Regenerative Medicine Products Market;

4.) The European Regenerative Medicine Products Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

Market Dynamics

The report analyzes the factors impacting the growth and the current market trends influencing the global Regenerative Medicine Products market. Detailed pricing information with ex-factory prices of various products by key manufacturers form a crucial part of the report. Competition analysis, along with regional government policies affecting the Regenerative Medicine Products market provides a detailed overview of the current status and prospects of the market. The impact of the ever-growing global population, coupled with technological advancements affecting the global Regenerative Medicine Products market is also covered in the report.

Drivers & Constraints

The report provides extensive information about the factors driving the global Regenerative Medicine Products market. Factors influencing the growth of the Regenerative Medicine Products market, along with technological advancements, are discussed extensively in the report. The current restraints of the market, limiting the growth and their future impact are also analyzed in the report. The report also discusses the impact of rising consumer demand, along with global economic growth on the Regenerative Medicine Products market.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.lexisbusinessinsights.com/request-sample-142529

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Statistical surveying reports are a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Director- Business Development)

US: +1 210 907 4145

6851 N Loop

1604 W San Antonio,

TX 78249

[emailprotected]

http://www.lexisbusinessinsights.com

Visit link:
Global Regenerative Medicine Products Market Size, Comprehensive Analysis, Development Strategy, Future Plans and Industry Growth with High CAGR by...

With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.

Roots Analysis is pleased to announce the publication of its recent study, titled, Global Stem Cells Market: Focus on Clinical Therapies, 20202030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)).

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Source of Stem Cell

Origin of Stem Cell

Type of Stem Cell

Lineage of Stem Cell

Route of Administration

Therapeutic Area

End Users

Key Geographical Regions

Transcripts of interviews held with the following senior level representatives of stakeholder companies

Key companies covered in the report

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

Follow this link:
Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030, claims Roots Analysis - Cheshire Media

Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Regenerative Medicine Market is Projected to Reach USD 17.9 Billion by 2025 from USD 8.5 Billion in 2020, at a CAGR of 15.9% during the Forecast Period.

Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline of regenerative medicine products. However, the high cost of cell and gene therapies and ethical concerns related to the use of embryonic stem cells in research and development are expected to restrain the growth of this market during the forecast period.

The cell therapies segment accounted for the highest growth rate in the regenerative medicine market, by product, during the forecast period

Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The cell therapies segment accounted for the highest growth rate in the regenerative medicine market in 2019. The increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders and the rising funding for the R&D of regenerative medicine products and therapies are the major factors driving the growth of this segment.

Oncology segment accounted for highest CAGR

Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the oncology segment accounted for the highest growth rate. This can be attributed to the rising prevalence of orthopedic diseases, growing geriatric population, increasing number of stem cell research projects, growing number of clinical researches/trials, and the rich pipeline of stem cell products for the treatment of musculoskeletal disorders.

Europe: The fastest-growing region regenerative medicine market

The global regenerative medicine market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. The North America region is projected to grow at the highest CAGR during the forecast period in 2019. The growth in the North American regenerative medicine market can be attributed to rising stem cell banking, tissue engineering, and drug discovery in the region; expansion of the healthcare sector; and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases.

Market Dynamics

Drivers

Restraints

Opportunities

Impact of the COVID-19 Pandemic on the Regenerative Medicine Market

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/6v7acf

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post here:
Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act - Stockhouse

Pune, India, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Global Molecular Diagnostics Market covered a value of USD 8012.7 Million in the year 2017 and is projected to reach USD 13873.6 Million by 2025. As per the report, the global market is expected to garner a healthy CAGR of 7.1% throughout the forecast period. The global molecular diagnostics market is projected to grow with rising technological developments in molecular diagnostic techniques. These advancements are intended to offer higher accuracy, cost-effectiveness, and portability which further drives the market. This information was published by Fortune Business Insights in a report. In 2017, North America market was valued at US$ 3639.4 Mn and is likely to lead the global landscape through the forecast period. The rising collaborations and association between research hospitals and academic institutions encourages growth of the market in this region.

Molecular Diagnostic Industry Developments:

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/molecular-diagnostics-market-100086

Infectious Diseases: The Largest Growing Segment Among Other Applications

Among applications, infectious diseases segment is expected to account for a majority of share in the global molecular diagnostic market. The scope of this segment is increasing owing to the rising number of patients suffering from infections and microbial outbreaks. Moreover, the infectious diseases segment covered a share of 60% in the year 2017.

Development of tests for several diseases and rising awareness about the benefits of adopting molecular diagnostic technologies may prevent the occurrence of infectious diseases. Global organizations such as World Bank and the World Health Organization (WHO) are planning to conduct awareness programs to increase the talent pool for molecular diagnostics.

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/molecular-diagnostics-market-100086

North America Continues to Maintain Its Stronghold until 2025

"Well-established healthcare infrastructure, combined with the rising incidence of cancer is helping the market grow in North America," stated a lead analyst at Fortune Business Insights. "Developed healthcare systems further helps in the easy availability and accessibility of advanced instruments such as molecular diagnostics.

In 2017, this regional market was valued at US$ 3639.4 Mn and is likely to lead the global landscape through the forecast period. The rising collaborations and association between research hospitals and academic institutions encourages growth of the market in this region. Both the bodies are involving in continuous discussions for process improvements in molecular diagnosis.

The market in Europe is also expected to witness considerable growth with growing emphasis on clinical microbiology and hospital research organizations. This is mainly done to increase the number of molecular diagnostic techniques. Rapidly developing healthcare infrastructure and rising investments in research and development activities are factors responsible for creating good growth opportunities.

Quick Buy - Molecular Diagnostics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100086

Abbott Launched a Next Generation System Used for Molecular Diagnosis

The global molecular diagnostics market is expected to be dominated by companies such as Danaher, Abbott, QIAGEN, and F. Hoffmann-La Roche Ltd. Strong supply chain network, rising research and development (R&D) activities, and development strategies are likely to create growth opportunities for the above companies.

In 2016, Abbott announced the introduction of a next-generation system called Alinity. This system is used for plasma and blood screening, haematology procedures, molecular diagnostics, and clinical chemistry. Companies are focussing on to develop new molecular diagnostic tests, which may foster growth of the market.

In 2018, Banyan Biomakers received marketing authorization from the U.S. FDA on its first blood diagnostic test. This test was developed to treat traumatic brain injuries which is also referred to as concussion among adults. These developments are likely to have a positive impact on the overall market.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/molecular-diagnostics-market-100086

Molecular Diagnostic Market Players:

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/molecular-diagnostics-market-100086

Molecular Diagnostic Market Segmentations:

By Product Type

Instruments

Reagents & Consumables

By Application

Infectious Disease

Blood Screening

Histology

Oncology

Others

By Technique

Amplification Techniques

Hybridization Techniques

Sequencing Techniques

Others

By End User

Hospitals

Clinical & Pathology Labs

Others

By Geography

North America (USA and Canada)

Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

Latin America (Brazil, Mexico and Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

SECONDARY DATA SOURCES THAT WE REFER TO:

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

Have a Look at Related Reports:

Active Wound Care Market Share and Global Trend by Product Type (Biological Skin Equivalents, Growth Factors, Biological Dressings), Indication (Diabetic Foot Ulcers, Pressure Ulcers, Lower Limb Ulcers), End User (Hospitals, Clinics, Home Care Settings) and Geography Forecast till 2025

Orthobiologics Market Share and Global Trend by Product Type (Viscosupplements, Bone Growth Stimulators, Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cells, Allografts), Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery), End User (Hospitals, Ambulatory Surgical Centers, Speciality Clinics) and Geography Forecast till 2025

X-Ray Flat Panel Detectors Market Share and Global Trend by Product Type (Amorphous, Silicon, Amorphous Selenium, Complementary Metal Oxide Semiconductor), Imaging type (Static, Dynamic), Type (Retrofit, New), Application (General Radiography, Dentistry, Oncology, Orthopedic) Geography Forecast till 2026

Bone Growth Stimulators Market Share and Global Trend By Product Type (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins (BMP), Platelet-Derived Growth Factor (PDGF)), By Application (Spinal Fusion, Maxillofacial & Dental, Nonunion and Union Bone Fractures), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Home Care), and Geography Forecast till 2026

Veterinary Drugs Market Share and Global Trend by By Product (Anti-infectives, Anti-inflammatory, Parasiticides, Others), By Animal (Companion, Livestock), By Route of Administration (Oral, Parenteral,Topical), Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Others,) and Geography Forecast till 2025

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/molecular-diagnostics-market-9028

View original post here:
Molecular Diagnostics Market to Record over 7% Growth Rate and Hit USD 13873.6 Million by 2025; Advancements in this Field to Increase Productivity...

UNITY Biotechnology Inc. (NASDAQ:UBX) has announced its Q3 2020 financial results and corporate updates. The company ended the quarter with cash and cash equivalents of $132.2 million at the end of the quarter, which is adequate to finance operations through mid-2022.

Anirvan Ghosh, the companys CEO, said that over the past quarter, the company focused its resources on cellular senescence programs in neurology and ophthalmology. Ghosh said that they built on the robust foundation of the senolytics platform and the company made considerable progress in advancing critical programs in its pipeline. The CEO said that they have deep conviction around the role of senescent cells in aging diseases, especially in the brain and eye. Recently the company commenced a phase 1 trial of UBX1325 in diabetic macular edema (DME).

The company completed Investigational New Drug (IND) application-enabling studies with UBX1325 in July 2020. UBX1325 is an experimental senolytic, small Molecule inhibitor of anti-apoptotic BCL-2 family member, BCL-xL. Already UNITY Biotechnology has commenced a Phase 1 UBX1325 safety study and dosing of the first patient occurred in October. If the clinical sites manage to recruit and retain investigators and study staff, they will be in a position to screen and enrol patients during the pandemic. The company expects preliminary study results in 1H 2021 after which it will initiate a proof of concept DME study. UNITYs overall clinical program will focus on the age-related disease of the eye like diabetic retinopathy and AMD.

The company announced the 12-week phase 2 UBX0101 study results in August 2020. UBx0101 is a p53/MDM2 interaction inhibitor the company is developing for the treatment of moderate-to-severe painful osteoarthritis of the knee. Results showed that there was no statistically significant difference between the UBX0101 arm and the placebo group at the 12-week endpoint for baseline change in WOMAC-A. WOMAC-A is the established pain measurement in osteoarthritis. Considering these results, the company doesnt expect to progress UBX0101 into vital studies and will report results in a future scientific meeting.

Visit link:
UNITY Biotechnology Inc. (NASDAQ:UBX) Announces Its Q3 2020 Financial Results And Progress of UBX1325 Development - BP Journal

iNtRON Biotechnology, Inc. (KOSDAQ:048530) shareholders should be happy to see the share price up 13% in the last month. But over the last half decade, the stock has not performed well. In fact, the share price is down 49%, which falls well short of the return you could get by buying an index fund.

View our latest analysis for iNtRON Biotechnology

While iNtRON Biotechnology made a small profit, in the last year, we think that the market is probably more focussed on the top line growth at the moment. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. It would be hard to believe in a more profitable future without growing revenues.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

It is of course excellent to see how iNtRON Biotechnology has grown profits over the years, but the future is more important for shareholders. This free interactive report on iNtRON Biotechnology's balance sheet strength is a great place to start, if you want to investigate the stock further.

iNtRON Biotechnology provided a TSR of 11% over the last twelve months. But that return falls short of the market. But at least that's still a gain! Over five years the TSR has been a reduction of 8% per year, over five years. It could well be that the business is stabilizing. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 3 warning signs for iNtRON Biotechnology that you should be aware of before investing here.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on KR exchanges.

PromotedIf you decide to trade iNtRON Biotechnology, use the lowest-cost* platform that is rated #1 Overall by Barrons, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

See the original post here:
iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years - Simply Wall St

Food Biotechnology Market with Covid-19 Impact Analysis: Forecast to Show Spurring Growth by 2020-2027 to its research database. The global Food Biotechnology Market research report is an output of a brief assessment and an extensive analysis of practical data collected from the global Food Biotechnology Market. The data are collected on the basis of industrial drifts and demands related to the services & products. The meticulously collected data offers for the process of effortless strategic planning. It also helps in creating promising business alternatives.

Free Sample Report + All Related Graphs & Charts @ https://www.statsandreports.com/request-sample/298517-global-food-biotechnology-market-size-status-and-forecast-2019-2025

Asia-Pacific region is expected to dominate the market over the forecast period owing to the increasing focus on the research, development, and manufacturing of Food Biotechnology in countries including China, Japan, India, and South Korea.

A perfect demonstration of the recent expansions and innovative technological resolutions offer our customers the liberty to develop their decision-making skills. This ultimately helps to work with perfect business alternatives and apply elegant implementations. The global Food Biotechnology Market report emphasizes the latest developments, growth, new opportunities, and dormant tricks. It provides an all-inclusive stance of the global Food Biotechnology Market. Requirement proportion and innovation of modern technologies are some of the key factors covered in the global Food Biotechnology Market report.

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

This helps to understand the overall market and to recognize the growth opportunities in the global Food Biotechnology Market. The report also includes a detailed profile and information of all the major market players currently active in the global Food Biotechnology Market. The companies covered in the report can be evaluated on the basis of their latest developments, financial and business overview, product portfolio, key trends in the market, long-term and short-term business strategies by the companies in order to stay competitive in the market.

We are currently offering Quarter-end Discount to all our high potential clients and would really like you to avail the benefits and leverage your analysis based on our report.

Grab Your Report at an Impressive Discount (Use Corporate email ID to Get Higher Priority) @ https://www.statsandreports.com/check-discount/298517-global-food-biotechnology-market-size-status-and-forecast-2019-2025

Some of the Major Market Player Profile Included in This Report is:

ABS Global, Arcadia Biosciences, AquaBounty Technologies, BASF Plant Science, Bayer CropScience AG, Camson Bio Technologies Ltd, Dow AgroSciences LLC, DuPont Pioneer, Evogene Ltd, Hy-Line International, KWS Group, Monsanto, Origin Agritech Limited, Syngenta AG

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Transgenic Crops, Synthetic Biology Derived Products.

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Animals, Plants and Other.

The greater part of the data gathered is presented in graphical form along with the related statistics. The global Food Biotechnology Market report demonstrates the functioning of the main market players, suppliers, and dealers in detail. The report also highlights the restraints and drivers impacting the global Food Biotechnology Market.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

The report analyzes various decisive constraints such as item price, production capability, profit & loss statistics, and transportation & delivery channels influencing the global Food Biotechnology Market. It also covers the analysis of other important elements such as market demands, advancements, and product developments, various organizations, and processes impacting the global Food Biotechnology Market. The global Food Biotechnology Market research report emphasizes a variety of modifications done that improve the work process of the global Food Biotechnology Market.

Get Customized Report in your Inbox within 24 hours at: https://www.statsandreports.com/enquiry-before/298517-global-food-biotechnology-market-size-status-and-forecast-2019-2025

A methodically structured Food Biotechnology Market research report is based on the primary and secondary resource. It portrays the data collected in a more communicative and expressive way allowing the customer to develop a well-structured plan to develop and expand their businesses in the estimated duration.

Promising Regions & Countries Mentioned in The Food Biotechnology Market Report:

North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Buy Full Copy Global Food Biotechnology Report 2020-2027 @ https://www.statsandreports.com/placeorder?report=298517-global-food-biotechnology-market-size-status-and-forecast-2019-2025&type=SingleUser

COVID-19- Current Scenario & Potential Impact

Various communities and companies are doing their best to function and perform, and eventually cope with the challenges raised by COVID-19 pandemic. The COVID-19 pandemic had a negative impact on the market size for the year 2020, with small and medium scale companies struggling to sustain their businesses in the near-term future. Industry leaders are now focusing to create new business practices to deal with crisis situations like COVID-19 pandemic.

The report presents a strategic analysis of the Food Biotechnology market through key drivers, challenges, opportunities, and growth contributors. Further, the market attractiveness index is provided based on five forces analysis.

The Food Biotechnology market delivers value to customers through reliable market size for 2019 on the basis of demand and price analysis. The report presents near term and long term forecast of the addressable Food Biotechnology market size to 2027.

(We customize your report according to your research need. Ask our sales team for report customization. [emailprotected] )

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us

Stats and Reports is a global market research and consulting service provider specialized in offering wide range of business solutions to their clients including market research reports, primary and secondary research, demand forecasting services, focus group analysis and other services. We understand that how data is important in todays competitive environment and thus, we have collaborated with industrys leading research providers who works continuously to meet the ever-growing demand for market research reports throughout the year.

Contact:

Stats and ReportsMangalam Chamber, Office No 16, Paud RoadSankalp Society, Kothrud, Pune, Maharashtra 411038Phone: +1 650-646-3808Email: [emailprotected]Website: https://www.statsandreports.comFollow Us on: LinkedIN | Twitter |

Here is the original post:
Food Biotechnology Market to Witness Astonishing Growth by 2027 | ABS Global, Arcadia Biosciences, AquaBounty Technologies and more - Cheshire Media

AMR information of the Global Agricultural Biotechnology Market report will surely grow business and improve return on investment (ROI). The report has been prepared by taking into account several aspects of marketing research and analysis which includes market size estimations, market dynamics, company & market best practices, entry level marketing strategies, positioning and segmentations, competitive landscaping, opportunity analysis, economic forecasting, industry-specific technology solutions, roadmap analysis, targeting key buying criteria, and in-depth benchmarking of vendor offerings. This Agricultural Biotechnology Market research report gives CAGR values along with its fluctuations for the specific forecast period.

Major Market Key Players: Agricultural Biotechnology Market

Syngenta AG, Monsanto, DuPont, Performance Plants Inc., Global Bio-Chem Technology Group, and ADAMA Agricultural Solutions are some of the key players in this industry

Download Exclusive Sample (XXX Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @ https://www.adroitmarketresearch.com/contacts/request-sample/113

Agricultural Biotechnology Market research report encompasses a far-reaching research on the current conditions of the industry, potential of the market in the present and the future prospects. By taking into account strategic profiling of key players in the industry, comprehensively analyzing their core competencies, and their strategies such as new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions, the report helps businesses improve their strategies to sell goods and services. This AMR research report is sure to help grow your business in several ways. Hence, the Agricultural Biotechnology Market report brings into the focus, the more important aspects of the market or industry.

The Global Agricultural Biotechnology Market Accounted For XXX USD Billion In 2017 And Is Projected To Grow At A CAGR Of XX% The Forecast Period Of 2018 To 2025. The Upcoming Market Report Contains Data For Historic Years 2016, The Base Year Of Calculation Is 2017 And The Forecast Period Is 2018 To 2025.

This Free report sample includes:

1.A brief introduction to the Agricultural Biotechnology Market research report.2.Graphical introduction of the regional analysis.3.Top players in the Agricultural Biotechnology Market with their revenue analysis.4.Selected illustrations of Agricultural Biotechnology Market insights and trends.5.Example pages from the Agricultural Biotechnology Market

The Agricultural Biotechnology Market report provides insights on the following pointers:1.Market Penetration: Comprehensive information on the product portfolios of the top players in the Agricultural Biotechnology Market.

2.Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

3.Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

4.Market Development: Comprehensive information about emerging markets. This report analyses the market for various segments across geographies.

5.Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Agricultural Biotechnology Market.

Table of Contents: Agricultural Biotechnology Market*Agricultural Biotechnology Market Overview*Global Economic Impact on Industry*Global Market Competition by Manufacturers*Global Production, Revenue (Value) by Region*Global Supply (Production), Consumption, Export, Import by Regions*Global Production, Revenue (Value), Price Trend by Type*Global Market Analysis by Application*Manufacturing Cost Analysis*Industrial Chain, Sourcing Strategy and Downstream Buyers*Marketing Strategy Analysis, Distributors/Traders*Market Effect Factors Analysis*Global Agricultural Biotechnology Market Forecast

Get Latest Free TOC of This Report @ https://www.adroitmarketresearch.com/industry-reports/agricultural-biotechnology-market

Some of the key questions answered in these Agricultural Biotechnology Market reports:

*What will the market growth rate, growth momentum or acceleration market carries during the forecast period?*Which are the key factors driving the Agricultural Biotechnology Market?*What was the size of the emerging Agricultural Biotechnology Market by value in 2019?*What will be the size of the emerging Agricultural Biotechnology Market in 2025?*Which region is expected to hold the highest market share in the Agricultural Biotechnology Market?*What trends, challenges and barriers will impact the development and sizing of the Global Agricultural Biotechnology Market?*What is sales volume, revenue, and price analysis of top manufacturers of Agricultural Biotechnology Market?*What are the Agricultural Biotechnology Market opportunities and threats faced by the vendors in the global Agricultural Biotechnology Market Industry?

With tables and figures helping analyze worldwide Global Agricultural Biotechnology Market growth factors, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

How will this Market Intelligence Report Benefit You?

1.The report offers statistical data in terms of value (US$) as well as Volume (units) till 2027.

2.Exclusive insight into the key trends affecting the Agricultural Biotechnology industry, although key threats, opportunities and disruptive technologies that could shape the Global Agricultural Biotechnology Market supply and demand.

3.The report tracks the leading market players that will shape and impact the Global Agricultural Biotechnology Market most.

4.The data analysis present in the Agricultural Biotechnology report is based on the combination of both primary and secondary resources.

5.The report helps you to understand the real effects of key market drivers or retainers on Agricultural Biotechnology business.Significant highlights covered in the Global Agricultural Biotechnology market include:

*In-depth market analysis, including information about current Agricultural Biotechnology market drivers and challenges

*An exhaustive study on the expected trends, changing market dynamics, and market intelligence

*Porters Five Forces analysis discussing the potentiality of buyers and sellers operating in the market, which is likely to help in developing efficient strategies

*Detailed analysis of the changing competitive scenario and thorough vendor analysis

Some Notable Report Offerings:

We will provide you an analysis of the extent to which the global Agricultural Biotechnology acquires commercial characteristics along with examples or instances of information that helps you to understand it better.

We will also help to identify customary/ standard terms and conditions, as like offers, worthiness, warranty, and others for the Agricultural Biotechnology industry.

Also, this report will help you to identify any trends to forecast Agricultural Biotechnology growth rates.

The analysed report will forecast the general tendency for supply and demand in Agricultural Biotechnology market.

Thanks for reading this article you can also get individual chapter wise section or region wise report version like North America, Europe, MEA or Asia Pacific.

Any Question | Speak to Analyst @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/113

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read more:
Agricultural Biotechnology Market (COVID-19 Analysis): Major Applications Projected to be the Most Attractive Segment during 2020-2027 - Cheshire...

Aimed at decoding specific market developments and forces ensuring sustainable growth in Global Food Biotechnology Market, new business intelligence report has been recently added to equip report readers, investors and manufacturing veterans with ample insights crucial to harness growth prognosis. The report gauges into historical events and identifies core growth steering practices adopted in the historical years to propagate revenue generation. Based on current status and optimum understanding on past developments, keen market investors and novel aspirants may well brainstorm lucrative business strategies to sustain long term growth and stability in Global Food Biotechnology Market.

Get a sample of the report @ https://www.orbisresearch.com/contacts/request-sample/5304247?utm_source=Manjiri

Core Indicator Analysis: Global Food Biotechnology MarketCompetitive Landscape: Besides identifying some the primary forerunners in the competition, this high end research report highlights details on top investor activities comprising product expansion, facility and technological improvements, R&D expeditions, pipeline investments as well as overall advertising and promotional investments that play crucial role in growth maximization and revenue sustenance amidst dynamics volatility.

Details pertaining to company profiles, product specifications, capacity and sales-based developments as well as pricing structure and revenue potential of each of the players reveal crucial market specific information that in turn influence mindful business decisions.

The Major Players Covered in Global Food Biotechnology Market are:ABS GlobalArcadia BiosciencesAquaBounty TechnologiesBASF Plant ScienceBayer CropScience AGCamson Bio Technologies LtdDow AgroSciences LLCDuPont PioneerEvogene LtdHy-Line InternationalKWS GroupMonsantoOrigin Agritech LimitedSyngenta AG

Global Food Biotechnology Market by Type:

Transgenic CropsSynthetic Biology Derived Products

Global Food Biotechnology Market by Application:

AnimalsPlantsOthers

Market segment by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

Read complete report @ https://www.orbisresearch.com/reports/index/covid-19-version-global-food-biotechnology-market-status-2015-2019-and-forecast-2020-2025-by-region-product-type-and-end-use?utm_source=Manjiri

Region-wise DevelopmentsAssessing the market through the growth span, 2020-25, this high-end report reflects past market developments and events besides identifying current events and trends that collectively aid in making accurate growth forecasts. Details on import and export potential as well as sales volume have been requisitely addressed in the report.

Regional assessment reveals details pertaining to growth status across specific growth spots, highlighting production and consumption developments, import and export activities as well as sales volume data that are crucial to render growth specific, high revenue incurring business decisions.

Segmentation by Product and ApplicationThis part of the report highlights versatile details on product improvisation, specifications aligning with customer expectations as well as volumetric growth advances. A clear perspective on application-based analysis of the Global Food Biotechnology Market has also been roped in the report to understand market size projections and dominant trend assessment that closely influence application derivatives.

The market also includes a detailed opportunity mapping section and driver assessment that result in systematic growth projections in Global Food Biotechnology Market.

For Enquiry before buying report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/5304247?utm_source=Manjiri

Key Player Analysis

The report also includes a clear perspective on vendor activities and accurately identifies frontline players. Details on their product and service-based investments, bargaining power, manufacturing practices and revenue generation patterns have also been decisively scanned to derive workable insights. Information thus furnished in these report sections are aimed at directing profitable business decisions amongst keen market investors as well as novice entrants eying systematic market entry.

COVID Assessment

Aimed at delivering appropriate details on concurrent market developments and growth initiators, a dedicated section on COVID-19 analysis has also been included in the report to offer appropriate pandemic management guidelines.

About Us:Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: ++91 895 659 5155

More:
Global Food Biotechnology Market Industry Analysis and Forecast (2020-2025), By Material Type, Product Type, Application, and Region. - Cheshire...

Global Plant Biotechnology Equipment Market 2025 Report Provides Porters Five Forces Analysis Illustrates the Potency of Buyers & Suppliers Operating in the Industry & the Quantitative Analysis of The Global Market from 2019 to 2025 is Provided to Determine the Market Potential.

Plant Biotechnology Equipment Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025The study of Plant Biotechnology Equipment market is a compilation of the market of Plant Biotechnology Equipment broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Plant Biotechnology Equipment industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Request a sample of Plant Biotechnology Equipment Market report @ https://hongchunresearch.com/request-a-sample/60575

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Plant Biotechnology Equipment industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

The following manufacturers are covered:Keygene(Netherlands)Heinz Walz GmbH (Germany)LemnaTec(Germany)Photon Systems Instruments(Czech Republic)Qubit Systems (Canada)Thermo Fisher Scientific (US)Tecan Group (Switzerland)LabRepCo (US)Geneq (Canada)Illumina (US)LGC Limited (UK)Evogene (Israel)

Access this report Plant Biotechnology Equipment Market @https://hongchunresearch.com/report/worldwide-plant-biotechnology-equipment-market-2019-60575

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeSensors ModulesImaging DevicesAutomated SystemDronesLED LightingPortable Devices

Segment by ApplicationPlant ResearchBreedingProduct DevelopmentQuality AssessmentOthers

For a global outreach, the Plant Biotechnology Equipment study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

To Check Discount of Plant Biotechnology Equipment Market @ https://hongchunresearch.com/check-discount/60575

Major Point of TOC:

Chapter One: Plant Biotechnology Equipment Market Overview

Chapter Two: Global Plant Biotechnology Equipment Market Competition by Manufacturers

Chapter Three: Global Plant Biotechnology Equipment Production Market Share by Regions

Chapter Four: Global Plant Biotechnology Equipment Consumption by Regions

Chapter Five: Global Plant Biotechnology Equipment Production, Revenue, Price Trend by Type

Chapter Six: Global Plant Biotechnology Equipment Market Analysis by Applications

Chapter Seven: Company Profiles and Key Figures in Plant Biotechnology Equipment Business

Chapter Eight: Plant Biotechnology Equipment Manufacturing Cost Analysis

Chapter Nine: Marketing Channel, Distributors and Customers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Plant Biotechnology Equipment Market Forecast

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Author List13.4 Disclaimer

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

Read this article:
Impact Of Covid-19 on Plant Biotechnology Equipment Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - Cheshire...

Precision medicine is in its nascent stages, but the field is rapidly growing, adding another catalyst to an already lengthy list for the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG).

One of the driving forces behind ARKGs enviable long-term track records is its the managers ability to identify disruptive forces in the healthcare and genomics arenas. The intersection of precision medicine and genomics could be the next growth frontier for ARKG investors.

Put simply, precision medicine is the application of technology to biology, and its one of the most innovative ideas in the healthcare arena.

Many precision-medicine techniques offer the potential for disease prevention, driving the potential for cost savings and patient-outcome improvements, said Dr. Charles Kennedy, CEO and managing partner at Blue Ox Healthcare Partners, in an interview with Barrons. One example is pre-term birth, which represents more than $32 billion in health-care spending in the U.S.in part due to its occurrence in one in every 10 pregnancies, and as many as one in every five pregnancies in the African American population. While many interventions are used to reduce the morbidity and mortality of pre-term birth, a fundamental problem that exists is the inability to identify women at risk for a pre-term delivery.

The intersection of precision medicine and genomics could be the next growth frontier for ARKG investors.

Everything about health care is changing and will continue to do so. Where you receive your care is evolving based on convenience and integration with daily life, said Kennedy. For example, weve seen more medical retail locations in shopping environments. Additionally, technology that remotely monitors patients who might otherwise need to be in a care setting is changing.

Gene sequencing and precision medicine are viewed as vital avenues for success in developing COVID-19 treatments. Bolstering the long-term case for genetic sequencing is the fields ability to help healthcare professionals more accurately diagnose ailments, delivering a higher level of personalized patient care.

While precision medicine might have only indirect impacts on issues such as access and costs, it transcends race by digitizing your biology and characterizing what makes you uniquely you, notes Kennedy in the Barrons interview. Simply put, you have the biology to take advantage of a drug or other treatment, or you dont. As such, more quantitative and discrete measures of disease and intervention opportunities make care more objective, less subjective, and more precisely aligned with the greatest likelihood of the best patient outcome, no matter who you are or where you come from.

For more on disruptive technologies, visit our Disruptive Technology Channel.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

Read more here:
How Precision Medicine Will Revolutionize Healthcare - ETF Trends

Study will expand access to antibody testing outside of laboratory settings

At present,mostantibody tests on the market require samples to be sent to a lab for analysis.The extra cost and time associated hasconstrainedpopulation wide studies ofSARS-CoV-2antibodies.

"An antibody test that can be done at the point of care without the need for a lab can more quickly provide information clinicians and administrators need to make decisions for their nursing home patients and staff," says Dr. Michael Fang, BASE10 CEO.

"This research is an important milestone in our efforts to expand access to antibody testing," says Elizabeth Freund, VP of Innovation at BASE10. "DNA Link's AccuFind performs very well in laboratory settings. The next logical step is to test its performance when used by healthcare professionals outside the lab. Many factors have the potential to affect test performance in lesser controlled settings so it's an ambitious goal to be sure. However, if FDA believes the data demonstrates its safety and effectiveness under these conditions, we'll be one step closer to FDA emergency use authorization for point of care use."

The study is set to launch in December.

About BASE10 Genetics, Inc.BASE10 is a precision medicine company based in Chicago. BASE10's proprietary platform identifies precision diagnostics technologies with high potential for improving health outcomes, and creates turnkey, disease management programs that can be deployed at scale for insurance payors.

For more information about BASE10 Genetics and its solutions, contact [emailprotected].

About DNA Link, Inc.DNA Link, Inc. is a leading genomic service corporation based in Korea with a focus on personalized medicine and new drug development. The company combines biotechnology with information & communications technology to support total analysis of genomic and clinical information to accelerate research and development in the field of bio-industry and genomic analysis industry.

For more information about DNA Link and its solutions, contact[emailprotected]

SOURCE BASE10 Genetics, Inc.

https://www.base10genetics.com/

Read this article:
BASE10 and DNA Link Partners on Research to Support Authorization of Antibody Test at the Point of Care - PRNewswire

Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December 31, 2020. He will be replaced as President and Chief Executive Officer by Thomas Burnell, PhD., effective December 1, 2020. Mr. Stover, who will step down from the Interpace Board of Directors once Dr. Burnell joins the company and is appointed to the Board, will serve as an advisor to the company through the middle of 2021 in order to support the transition.

Dr. Burnell joins Interpace with significant leadership experience with numerous healthcare companies, including a number of specialty clinical laboratories. This includes serving as President & CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories and Eurofins Scientific, Inc. in addition to senior leadership roles with other companies such as Elite One Source, Nebraska Heart Institute, and most recently with the Pioneer Heart Institute.

Robert Gorman, Chairman of the Board for Interpace, commented, On behalf of the Board, I thank Jack for his leadership and service to the company. He has led the company through both difficult and transformational times, and has helped to position the company for strong growth in the future.

After careful reflection, I have decided that now is the right time to retire and help the company through a thoughtful succession process, said Mr. Stover. It has been a privilege to lead Interpace over the past four years, and I am proud to have been a part of the phenomenal team of dedicated professionals at Interpace which has worked tirelessly to improve the care of patients suspected of having cancer.

Dr. Burnell added, I am thrilled to join the Interpace team at such an exciting and pivotal point in the companys history. Interpace has a strong reputation as a patient-centric organization, and over the years has developed an impressive product and service offering that is particularly critical given the challenging demands of cancer care. I look forward to working with the entire leadership team to continue the companys growth as a leading provider of specialty oncology-focused diagnostic services and customized pharma services.

About Interpace Biosciences

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through Interpace Diagnostics, provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advance personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Companys future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including believes, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 10-K filed on April 22, 2020, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:Investor RelationsEdison GroupJoseph Green/ Megan Paul(646) 653-7030 / 7034jgreen@edisongroup.com / mpaul@edisongroup.com

Read more:
Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as...

DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in Gene Therapy, Automated Bioanalytics, and Biomarker Platforms" report has been added to ResearchAndMarkets.com's offering.

The research provides technological insights across inflammation, infectious diseases, and microbiomics.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Innovations in Life Sciences, Health & Wellness from:

For more information about this report visit https://www.researchandmarkets.com/r/tkufmb

Continued here:
2020 Report: Growth Opportunities in Gene Therapy, Automated Bioanalytics, and Biomarker Platforms - ResearchAndMarkets.com - Business Wire

Precision-Medicine-MarketOverview of Precision Medicine Market 2020-2026:

Global Precision Medicine Market 2020 research report presents analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global market. Research reports analyses the major opportunities, CAGR, yearly growth rates to help the readers to understand the qualitative and quantitative aspects of theGlobal Precision MedicineMarket. The competition landscape, company overview, financials, recent developments and long-term investments related to theGlobal Precision Medicine Marketare mentioned in this report.

The key segments covered in this report are geographical segments, end-use/application segments, and competitor segments. The local segment, regional supply, application, and wise demand, major players, prices are also available by 2026. Global Precision Medicine Market are mentioned in the competition landscape, company overview, financials, recent developments and long-term investments.

Get PDF Sample Copy of the Report (Including Full TOC, List of Tables & Figures, Chart):https://www.marketinforeports.com/Market-Reports/Request-Sample/217480

Top Key players profiled in the Precision Medicine market report include:Johnson & Johnson, IBM, GE Healthcare, Illumina, Roche, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Novartis, Abbott Laboratories, Almac Group, Intel Corporation, Biomrieux Sa, Cepheid, Qiagen, Randox Laboratories, Healthcore and More

Based on the type of product, the global Precision Medicine market segmented into: Diagnostics TherapiesBased on the end-use, the global Precision Medicine market classified into: Oncology Neurosciences Immunology Respiratory Others

global Precision Medicine market report also highlights key insights on the factors that drive the growth of the market as well as key challenges that are required to Precision Medicine market growth in the projection period. Here provide the perspectives for the impact of COVID-19 from the long and short term. Precision Medicine market contain the influence of the crisis on the industry chain, especially for marketing channels. Update the industry economic revitalization plan of the country-wise government.

To Understand the influence of COVID-19 on the Set Screw Market with our analysts monitoring the situation across the globe. Get here sample analysis

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026Regions Covered in the Global Precision Medicine Market:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Key questions answered in this report:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketinforeports.com/Market-Reports/Request_discount/217480

Key point summary of the Global Precision Medicine Market report:

Detailed TOC of Precision Medicine Market Report 2020-2026:Chapter 1: Precision Medicine Market OverviewChapter 2: Economic Impact on IndustryChapter 3: Market Competition by ManufacturersChapter 4: Production, Revenue (Value) by RegionChapter 5: Supply (Production), Consumption, Export, Import by RegionsChapter 6: Production, Revenue (Value), Price Trend by TypeChapter 7: Market Analysis by ApplicationChapter 8: Manufacturing Cost AnalysisChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Precision Medicine Market ForecastContinued

For More Information with full TOC: https://www.marketinforeports.com/Market-Reports/217480/Precision-Medicine-market

Customization of the Report: Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]: https://www.marketinforeports.com/Market-Reports/Request-Customization/217480/Precision-Medicine-market

Get in Touch with Us :Mr. Marcus KelCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Email: s[emailprotected]Website: http://www.marketinforeports.com

Read more from the original source:
Latest Research report on Precision Medicine Market Size predicts favorable growth and forecast 2020 2026| By Top Leading Vendors like Johnson &...

Nov. 23, 2020 08:00 UTC

GHENT, Belgium--(BUSINESS WIRE)-- Novalis Biotech, an early stage venture capital investor in technologies to revolutionize healthcare, announced today the successful first closing of its second fund, Novalis Biotech Acceleration, raising an initial 8 million. With commitments for a similar amount already in place, Novalis anticipates a final closing in early 2021. The majority of investors in Novalis first fund have co-invested in this first closing.

We have already doubled our first fund in this closing and with the commitments in place we are almost fully subscribed to reach our goal of 25 million. With the addition of a couple new investors, we remain on track to fully close the Acceleration Fund in early 2021, said Jan Van den Berghe, co-founder of Novalis.

For the Novalis Acceleration Fund, investments will be split between approximately 10 early stage incubation projects and about 10 acceleration projects, where the investment in each company is larger. Two initial investments have been identified and will close in the near future.

Novalis investment strategy creates a unique ecosystem for healthcare start-ups based on solid foundations of strong scientific and business expertise. The company provides hands-on support for start-ups, allowing an idea to be built into a successful company. In todays disruptive world of new technologies in healthcare like genomics, bioinformatics, diagnostics, personalized medicine, Novalis vision is to bring better healthcare for patients.

Novalis invests early and focuses on capital light ideas, where a relatively small investment can create significant value through the use of software, IP, tools, and other technology that can serve and benefit healthcare. Leveraging extensive academic networks, Novalis translates innovation to viable companies that able to deliver on the founding scientific promise.

Our investment strategy for Fund 1 was very successful. Each company brings a unique perspective to healthcare, many of which are based on our own ideas, said Wim van Criekinge. We will continue this strategy into the Acceleration Fund as well as look at companies where our investment will drive process. There are already a number of companies we have identified for investment as well as plans to incubate a further company based on our internal assessments.

Novalis Fund 1 totalled 4 million that was deployed into eight companies, mostly in the Benelux region, which focused on genomics, bioinformatics and digital health. These include BioLizard, Cergentis, Enzyre, Epify, Fertiga, myNEO and OHMX.bio. Geographically, the exception was its investment in doc.ai, a digital health company based in the U.S. For Fund 2, Novalis will expand to other areas in Europe and make additional investments in the U.S.

About Novalis

Novalis provides seed funding and ongoing support to biotechnology and life sciences companies. Novalis incubates and advances its own ideas or supports existing innovative life science start-ups. The companys core competence lies in the interaction between bioinformatics, genomics, and digitalization in the life sciences industry. Novalis strongly believes in applying innovative information technology to advance the prevention, diagnosis, or treatment of a disease. For more information, please visit http://www.noval.is.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005574/en/

More here:
Novalis Biotech Announces First Closing of its Second Healthcare Fund - BioSpace